Welcome to our dedicated page for Pulmonx SEC filings (Ticker: LUNG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pulmonx Corporation (Nasdaq: LUNG) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, periodic reports, and exhibits filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into Pulmonx’s financial condition, executive transitions, compensation arrangements, and key business developments related to its minimally invasive treatments for COPD and severe emphysema.
Pulmonx uses Form 8-K to report material events such as quarterly financial results and management changes. For example, a July 2025 Form 8-K furnished a press release titled “Pulmonx Reports Second Quarter 2025 Financial Results,” while an October 2025 Form 8-K described the resignation of the then-President and Chief Executive Officer, the appointment of Glen French as President and Chief Executive Officer, and the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer. That filing also outlined separation agreements, consulting arrangements, and equity grants for departing and incoming executives.
Through its SEC filings, Pulmonx also discloses equity compensation structures, including restricted stock units (RSUs) and performance stock units (PSUs) granted under its equity incentive plans and inducement plans. The terms of these awards, such as time-based vesting schedules and stock price performance conditions, are described in detail in the exhibits to the filings.
On Stock Titan, Pulmonx filings are updated in step with the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Investors can quickly identify information on quarterly and annual results, executive employment terms, severance and change in control plans, and other governance matters without reading every page of each filing. The filings page also helps users locate references to non-GAAP metrics like Adjusted EBITDA and constant currency revenue, which Pulmonx discusses in its earnings-related disclosures.
David Aaron Lehman, identified as General Counsel and officer of Pulmonx Corporation (ticker LUNG), reported four separate non-derivative stock dispositions on 09/02/2025. The Form 4 shows Mr. Lehman sold 929, 3,541, 2,068 and 3,231 shares, each at $1.60 per share. Each sale is explained as occurring to cover tax withholding obligations tied to Restricted Stock Units that vested from grants dated March 1, 2022, March 1, 2023, March 1, 2024, and March 3, 2025, respectively. The filing reports the reporting-person’s beneficial ownership following these transactions as 272,110, 268,569, 266,501 and 263,270 shares (direct ownership) after each reported disposition. The Form 4 is signed by Mr. Lehman on 09/03/2025.